Safety and effectiveness of ataluren in patients with nonsense mutation DMD in the STRIDE Registry compared with the CINRG Duchenne Natural History Study (2015–2022): 2022 interim analysis

[1]  F. Muntoni,et al.  DMD Genotypes and Motor Function in Duchenne Muscular Dystrophy , 2023, Neurology.

[2]  Eugenio Mercuri.  Propensity score matching methodology , 2022, Video Journal of Biomedicine.

[3]  Jay J. Han,et al.  Effect of Different Corticosteroid Dosing Regimens on Clinical Outcomes in Boys With Duchenne Muscular Dystrophy: A Randomized Clinical Trial. , 2022, JAMA.

[4]  M. Main,et al.  Investigating the role of dystrophin isoform deficiency in motor function in Duchenne muscular dystrophy , 2022, Journal of cachexia, sarcopenia and muscle.

[5]  F. Muntoni,et al.  Ataluren delays loss of ambulation and respiratory decline in nonsense mutation Duchenne muscular dystrophy patients , 2021, Journal of comparative effectiveness research.

[6]  V. Ricotti,et al.  Genotype‐related respiratory progression in Duchenne muscular dystrophy—A multicenter international study , 2021, Muscle & nerve.

[7]  H. Lochmüller,et al.  Life expectancy at birth in Duchenne muscular dystrophy: a systematic review and meta-analysis , 2020, European Journal of Epidemiology.

[8]  E. Mercuri,et al.  Safety and effectiveness of ataluren: comparison of results from the STRIDE Registry and CINRG DMD Natural History Study , 2020, Journal of comparative effectiveness research.

[9]  E. Mercuri,et al.  Ataluren use in patients with nonsense mutation Duchenne muscular dystrophy: patient demographics and characteristics from the STRIDE Registry. , 2019, Journal of comparative effectiveness research.

[10]  S. Pandya,et al.  Palliative care services in families of males with muscular dystrophy: Data from MD STARnet , 2019, SAGE open medicine.

[11]  Carla M Bann,et al.  Diagnosis and management of Duchenne muscular dystrophy, part 2: respiratory, cardiac, bone health, and orthopaedic management , 2018, The Lancet Neurology.

[12]  S. Pandya,et al.  Diagnosis and management of Duchenne muscular dystrophy, part 1: diagnosis, and neuromuscular, rehabilitation, endocrine, and gastrointestinal and nutritional management , 2018, The Lancet Neurology.

[13]  R. Finkel,et al.  Ataluren in patients with nonsense mutation Duchenne muscular dystrophy (ACT DMD): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial , 2017, The Lancet.

[14]  Juan Yang,et al.  Serum Creatinine Distinguishes Duchenne Muscular Dystrophy from Becker Muscular Dystrophy in Patients Aged ≤3 Years: A Retrospective Study , 2017, Front. Neurol..

[15]  G. Comi,et al.  Diagnosis of Duchenne Muscular Dystrophy in Italy in the last decade: Critical issues and areas for improvements , 2017, Neuromuscular Disorders.

[16]  J. Kleijnen,et al.  The burden, epidemiology, costs and treatment for Duchenne muscular dystrophy: an evidence review , 2017, Orphanet Journal of Rare Diseases.

[17]  E. Pegoraro,et al.  Genetic diagnosis as a tool for personalized treatment of Duchenne muscular dystrophy , 2016, Acta myologica : myopathies and cardiomyopathies : official journal of the Mediterranean Society of Myology.

[18]  K. Bushby,et al.  European Cross-Sectional Survey of Current Care Practices for Duchenne Muscular Dystrophy Reveals Regional and Age-Dependent Differences , 2016, Journal of neuromuscular diseases.

[19]  A. Jacobson,et al.  Ataluren stimulates ribosomal selection of near-cognate tRNAs to promote nonsense suppression , 2016, Proceedings of the National Academy of Sciences.

[20]  E. Hoffman,et al.  P.103 DMD genotypes and loss of ambulation in the CINRG Duchenne natural history study , 2016, Neuromuscular Disorders.

[21]  S. Kurtz,et al.  Statistics in Brief: An Introduction to the Use of Propensity Scores , 2015, Clinical orthopaedics and related research.

[22]  Francesco Muntoni,et al.  The NorthStar Ambulatory Assessment in Duchenne muscular dystrophy: considerations for the design of clinical trials , 2015, Journal of Neurology, Neurosurgery & Psychiatry.

[23]  G. Comi,et al.  Ataluren treatment of patients with nonsense mutation dystrophinopathy , 2014, Muscle & nerve.

[24]  Juliet A. Ellis,et al.  International Workshop : Newborn screening for Duchenne muscular dystrophy 14 – 16 th December , 2012 , Naarden , The Netherlands , 2013 .

[25]  Jay J. Han,et al.  The cooperative international neuromuscular research group duchenne natural history study—a longitudinal investigation in the era of glucocorticoid therapy: Design of protocol and the methods used , 2013, Muscle & nerve.

[26]  S. Peltz,et al.  Ataluren as an agent for therapeutic nonsense suppression. , 2013, Annual review of medicine.

[27]  G. Comi,et al.  24 Month Longitudinal Data in Ambulant Boys with Duchenne Muscular Dystrophy , 2013, PloS one.

[28]  J. Pépin,et al.  Motor and respiratory heterogeneity in Duchenne patients: implication for clinical trials. , 2012, European journal of paediatric neurology : EJPN : official journal of the European Paediatric Neurology Society.

[29]  Craig McDonald,et al.  Diagnosis and management of Duchenne muscular dystrophy, part 2: implementation of multidisciplinary care , 2010, The Lancet Neurology.

[30]  P. Calverley,et al.  Changes in spirometry over time as a prognostic marker in patients with Duchenne muscular dystrophy. , 2001, American journal of respiratory and critical care medicine.

[31]  C. McDonald,et al.  Advances in pulmonary care in duchenne muscular dystrophy , 2017 .